Frontline Treatment Options in Advanced RCC

Panelists discuss the rapidly evolving frontline management of advanced renal cell carcinoma, highlighting progress in combination immunotherapy, precision-based treatment, toxicity management, and the promise of emerging therapies that are reshaping the standard of care.

EP. 1: Important Background Information on Advanced Renal Cell Carcinoma

October 29th 2025

Panelists discuss the epidemiology, histologic diversity, and evolving biology of advanced renal cell carcinoma, setting the stage for modern treatment selection.

EP. 2: Guideline-Recommended First-Line Treatments for Renal Cell Carcinoma

October 29th 2025

Panelists review current guideline-endorsed first-line treatment options for advanced renal cell carcinoma, emphasizing immunotherapy- and VEGF inhibitor–based combination regimens.

EP. 3: Key Clinical Trial Results for First-Line Treatments for Renal Cell Carcinoma

November 5th 2025

Panelists analyze landmark clinical trial data supporting current frontline RCC therapies, focusing on response rates, progression-free survival, and overall benefit across risk groups.

EP. 4: Adjuvant Therapy Considerations in Renal Cell Carcinoma

November 5th 2025

Panelists discuss evolving evidence supporting adjuvant therapy in renal cell carcinoma and how these findings inform clinical decision-making.

EP. 5: Adverse Event Management and Dosing of Immunotherapies and Tyrosine Kinase Inhibitors

November 12th 2025

Panelists discuss strategies for recognizing, preventing, and managing toxicities associated with frontline combination regimens in advanced renal cell carcinoma.

EP. 6: Recent Advances in Different Subtypes of Renal Cell Carcinoma

November 12th 2025

Panelists explore histology-specific and molecularly guided approaches that are expanding treatment options across renal cell carcinoma subtypes.

EP. 7: Future Directions in Renal Cell Carcinoma

November 19th 2025

Panelists discuss emerging research directions and novel therapeutic combinations poised to shape the next generation of renal cell carcinoma management.